Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure.
We report on 3 siblings (2 females and 1 male) with chronic progressive external ophthalmoplegia (CPEO), compatible with inherited mitochondrial cytopathy. The younger of the two sisters died at the age of 37 due to progressive respiratory failure. The older one presented with a status epilepticus at the age of 39 and was treated with valproate. Five months after the start of treatment, she developed fulminant liver failure and died. The brother has suffered from CPEO since early childhood but has had so far no other symptoms of a mitochondrial disease. A muscle biopsy from the younger sister revealed ragged-red fibers and decreased activities of complex I and IV of the respiratory chain but no pathogenic mutations in the mitochondrial tRNA genes or in several locations in the coding region of the mitochondrial genome. In the older sister's liver (obtained post-mortem), mitochondrial DNA was fragmented and could not be investigated. The clinical presentation and the biochemical findings suggest that all 3 siblings suffered from a mitochondrial cytopathy. Since mitochondrial cytopathies and valproate-induced fulminant liver failure are both rare events, an association between them is likely. Mitochondrial diseases should therefore be considered as a risk factor for valproate-induced liver failure and be excluded before treatment with valproate.
Krähenbühl
S
S
Department of Clinical Pharmacology, University of Berne, Switzerland.
Brandner
S
S
Kleinle
S
S
Liechti
S
S
Straumann
D
D
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D000075202:Contraindications; D004272:DNA, Mitochondrial / Q000032:analysis; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017240:Mitochondrial Myopathies / Q000150:complications* / Q000188:drug therapy; D017246:Ophthalmoplegia, Chronic Progressive External / Q000150:complications; D010088:Oxidoreductases / Q000378:metabolism; D012343:RNA, Transfer / Q000032:analysis; D012307:Risk Factors; D014635:Valproic Acid / Q000009:adverse effects*
D000927:Anticonvulsants; D004272:DNA, Mitochondrial; D014635:Valproic Acid; D012343:RNA, Transfer; D010088:Oxidoreductases